ivermectin oral / Generic mfg. 
Welcome,         Profile    Billing    Logout  
  Diseases    Trials    Trials    News 


«12345678910111213...129130»
  • ||||||||||  LY2090314 / Eli Lilly
    Journal:  Novel selective inhibitors of macropinocytosis-dependent growth in pancreatic ductal carcinoma. (Pubmed Central) -  Jul 28, 2024   
    Their ability to impair albumin-dependent proliferation was replicated both in different 2D cell culture systems and 3D organotypic models. These findings provide a new set of compounds specifically targeting macropinocytosis, which could have therapeutic applications in cancer and infectious diseases.
  • ||||||||||  ivermectin oral / Generic mfg.
    Journal:  Scratching beneath the surface: An evaluation of the management of scabies 2017-2023. (Pubmed Central) -  Jul 28, 2024   
    Use of ivermectin has risen in the last year suggesting that second-line treatment is increasingly needed for eradication. Whilst treatment failure may be due to non-compliance with treatment and decontamination efforts for both index and contacts, the more recent change in findings could be attributed to a fall in permethrin efficacy.
  • ||||||||||  ivermectin oral / Generic mfg.
    Review, Journal:  Scabies vaccines: where we stand and challenges ahead. (Pubmed Central) -  Jul 28, 2024   
    This review aims to provide a comprehensive overview of the ongoing challenges regarding the currently available control measures for scabies. It also explores the promising path of scabies vaccine development, highlighting the current state of research and challenges that need to be addressed to develop new and innovative measures for both treating and preventing scabies infections.
  • ||||||||||  ivermectin oral / Generic mfg.
    Journal:  ACV with/without IVM: a new talk on intestinal CDX2 and muscular CD34 and Cyclin D1 during Trichinella spiralis infection. (Pubmed Central) -  Jul 23, 2024   
    The current study assessed the efficacy of Acyclovir (ACV) and Ivermectin (IVM) as monotherapies and combined treatments for intestinal and muscular stages of Trichinella spiralis infection...The molecular tumorigenic effect of the nematode remains questionable. Nevertheless, IVM +ACV appeared to be a promising anthelminthic anti-inflammatory combination that, in parallel, rectified CDX2, CyclinD1, and CD34 expressions.
  • ||||||||||  Rupex (rupatadine) / Incepta Pharma, Medexus
    Journal:  Antihistamines H1 as Potential Anthelmintic Agents against the Zoonotic Parasite Angiostrongylus cantonensis. (Pubmed Central) -  Jul 22, 2024   
    The findings revealed four active compounds (promethazine, cinnarizine, desloratadine, and rupatadine), with promethazine demonstrating the highest potency (EC50 = 31.6 ?M)...Furthermore, an analysis of the physicochemical and pharmacodynamic properties of antihistamines revealed that their anthelmintic activity does not correlate with their activity at H1 receptors. This study marks the first documentation of antihistamines' activity against A. cantonensis, offering a valuable contribution to the quest for novel agents effective against zoonotic helminths.
  • ||||||||||  ivermectin oral / Generic mfg., albendazole / Generic mfg.
    Journal:  Successful Treatment of Cutaneous Larva Migrans With Combined Albendazole and Ivermectin Therapy: A Report of Two Cases From Sudan. (Pubmed Central) -  Jul 18, 2024   
    A 42-year-old man from Kordofan and a 38-year-old man from White Nile State presented with characteristic lesions on their lower extremities, resolving completely within one week post-treatment without recurrence. This report highlights the potential of combined albendazole-ivermectin therapy in managing CLM amid emerging antihelminthic resistance, suggesting that its broader application warrants further investigation.
  • ||||||||||  albendazole / Generic mfg.
    Enrollment closed, Combination therapy:  Iverped: Efficacy, Safety and Acceptability of Ivermectin ODT in PSAC (clinicaltrials.gov) -  Jul 15, 2024   
    P2,  N=210, Active, not recruiting, 
    This report highlights the potential of combined albendazole-ivermectin therapy in managing CLM amid emerging antihelminthic resistance, suggesting that its broader application warrants further investigation. Recruiting --> Active, not recruiting
  • ||||||||||  ivermectin oral / Generic mfg.
    Clinical guideline, Review, Journal:  Clinical practice guidelines for the diagnosis and treatment of scabies. (Pubmed Central) -  Jun 26, 2024   
    In cases where topical therapy proves inadequate or in instances of crusted scabies, oral ivermectin is recommended as a systemic treatment option. This comprehensive approach addresses the diagnostic and therapeutic challenges associated with scabies, optimizing patient care, and management outcomes.
  • ||||||||||  Natroba (spinosad) / Royalty
    Review, Journal:  Drugs for head lice. (Pubmed Central) -  Jun 21, 2024   
    This comprehensive approach addresses the diagnostic and therapeutic challenges associated with scabies, optimizing patient care, and management outcomes. No abstract available
  • ||||||||||  ivermectin oral / Generic mfg., levamisole / Generic mfg.
    Preclinical, Journal:  Genome-wide RNA interference of the nhr gene family in barber's pole worm identified members crucial for larval viability in vitro. (Pubmed Central) -  Jun 16, 2024   
    Using an in vitro biosystem, we demonstrated that 40 nhr genes in a blood-feeding nematode Haemonchus contortus (clade V; barber's pole worm) were responsive to host serum and one nhr gene (i.e., nhr-64) was consistently stimulated by anthelmintics (i.e., ivermectin, thiabendazole and levamisole); Using a high-throughput RNA interference platform, we knocked down 43 nhr genes of H. contortus and identified at least two genes that are required for the viability (i.e., nhr-105) and development (i.e., nhr-17) of the infective larvae of this parasitic nematode in vitro. Harnessing this preliminary functional atlas of nhr genes for H. contortus will prime the biological studies of this gene family in nematode genetics, infection, and anthelmintic metabolism within host animals, as well as the promising discovery of novel intervention targets.
  • ||||||||||  ivermectin oral / Generic mfg.
    Trial completion, Enrollment change:  SCRATCH: Oral Ivermectin Versus Topical Permethrin to Treat Scabies in Children and Adults (clinicaltrials.gov) -  Jun 13, 2024   
    P3,  N=1092, Completed, 
    Harnessing this preliminary functional atlas of nhr genes for H. contortus will prime the biological studies of this gene family in nematode genetics, infection, and anthelmintic metabolism within host animals, as well as the promising discovery of novel intervention targets. Unknown status --> Completed | N=502 --> 1092
  • ||||||||||  Veramyst (fluticasone furoate nasal spray) / GSK
    Trial completion date:  ACTIV-6: COVID-19 Study of Repurposed Medications (clinicaltrials.gov) -  Jun 11, 2024   
    P3,  N=15000, Active, not recruiting, 
    Unknown status --> Completed | N=502 --> 1092 Trial completion date: Jun 2024 --> Nov 2024
  • ||||||||||  ivermectin oral / Generic mfg.
    Journal:  Lab-made CO2 laser-engraved electrochemical sensors for ivermectin determination. (Pubmed Central) -  Jun 11, 2024   
    The developed method was successfully applied to direct analysis of pharmaceutical tablets, tap water (recovery of 94%) and synthetic urine samples (recovery between 97% and 113%). These results demonstrate the feasibility of the method for routine analyses involving environmental samples.
  • ||||||||||  ivermectin oral / Generic mfg.
    Journal:  Effect of drug therapies on self-reported chemosensory outcomes after COVID-19. (Pubmed Central) -  Jun 10, 2024   
    Independent predictors included demographic and clinical variables, in addition to specific medications used to mitigate disease symptoms (i.e., systemic corticosteroids, oseltamivir, vitamin C, ibuprofen, hydroxychloroquine, azithromycin, ivermectin, nitazoxanide, anticoagulants, and zinc)...No medication employed during the first months after SARS-CoV-2 infection had a clear positive effect on returning self-reported smell or taste function to normal, although nitrazoxide trended in a positive direction. Oral zinc had a negative effect on the reported recovery of these senses.
  • ||||||||||  albendazole / Generic mfg.
    Enrollment open, Combination therapy:  Iverped: Efficacy, Safety and Acceptability of Ivermectin ODT in PSAC (clinicaltrials.gov) -  Jun 7, 2024   
    P2,  N=210, Recruiting, 
    Oral zinc had a negative effect on the reported recovery of these senses. Not yet recruiting --> Recruiting
  • ||||||||||  moxidectin / Generic mfg., ivermectin oral / Generic mfg., albendazole / Generic mfg.
    Enrollment open:  Safety and Efficacy of Novel Combination Regimens for Treatment of Onchocerciasis (clinicaltrials.gov) -  Jun 3, 2024   
    P2,  N=300, Enrolling by invitation, 
    No abstract available Not yet recruiting --> Enrolling by invitation
  • ||||||||||  ivermectin oral / Generic mfg.
    Trial primary completion date:  ISSC: Ivermectin Safety in Small Children (clinicaltrials.gov) -  May 20, 2024   
    P2,  N=399, Recruiting, 
    Our data could help in the development of health education measures to reduce SM among undergraduate students and guide the population regarding the risks of this practice. Trial primary completion date: Apr 2024 --> Dec 2024
  • ||||||||||  ivermectin oral / Generic mfg.
    Trial completion:  A Phase III Confirmatory Study of K-237 (clinicaltrials.gov) -  May 20, 2024   
    P3,  N=1030, Completed, 
    Trial primary completion date: Apr 2024 --> Dec 2024 Active, not recruiting --> Completed
  • ||||||||||  ivermectin oral / Generic mfg.
    Journal:  Ivermectin performance in horses diagnosed with equine endocrine disorders. (Pubmed Central) -  May 16, 2024   
    However, due to the small group sizes, these data should be interpreted with caution. Nonetheless, results do indicate a need for further investigation of the possible influence of endocrine disorders on anthelmintic performance in horses.
  • ||||||||||  ivermectin oral / Generic mfg.
    Journal:  Pharmaceutical messianism and the politics of COVID-19 in the United States. (Pubmed Central) -  May 8, 2024   
    Utilising the framework of 'pharmaceutical messianism', our article focuses on three such cures - hydroxychloroquine, ivermectin, and monoclonal antibodies - to explore how pharmaceuticals were mobilised within politicised pandemic discourses...Moreover, we argue that aside from the affordability of the treatments being studied and the heterodox knowledge claiming their efficacy, the widespread uptake of these cures was also informed by popular medical (including immunological) knowledge, pre-existing attitudes toward 'orthodox' measures like vaccines and masks, and mistrust toward authorities and institutions identified with the 'medical establishment'. Taken together, our case studies affirm the recurrent nature of pharmaceutical messianism in times of health crises - while also refining the concept and exposing its limitations.
  • ||||||||||  ivermectin oral / Generic mfg.
    Journal:  Prescribing Patterns of Nonrecommended Medications for Children With Acute COVID-19. (Pubmed Central) -  May 8, 2024   
    Hydroxychloroquine (HCQ) and ivermectin were prescribed in 0.03% and 0.14% of COVID-19 cases, respectively, during nonrecommended periods (after September 12, 2020 for HCQ and February 5, 2021 for ivermectin) with considerable variation by state...Understanding overuse patterns can help mitigate downstream consequences of misinformation. Reaching providers and parents with clear evidence-based recommendations is crucial to children's health.
  • ||||||||||  moxidectin / Generic mfg., ivermectin oral / Generic mfg., albendazole / Generic mfg.
    Biomarker, Journal:  Biomarkers of gastrointestinal nematodes in beef cattle raised in a tropical area. (Pubmed Central) -  May 7, 2024   
    In the second step, pepsinogen was assessed in cattle of the Nelore breed distributed among three groups: infected (not treated with anthelmintic), MOX (treated with moxidectin), and IVM?+?BZD (treated with ivermectin?+?albendazole)...In the second study, a reduction in pepsinogen was found after anthelmintic treatment. Therefore, pepsinogen is a promising biomarker of worms in cattle naturally infected by the genera Haemonchus and Cooperia in tropical areas.
  • ||||||||||  ivermectin oral / Generic mfg.
    Journal:  Field sensitivity and specificity of the SD BIOLINE onchocerciasis IgG4 Rapid Diagnostic Test in children <10 (Pubmed Central) -  May 6, 2024   
    When the Ov16 Rapid Diagnostic Test was considered as the gold standard, the skin snip exhibited a sensitivity of 11.5% and a specificity of 99.5%. These results are similar to other studies comparing the performance of the Ov16 ELISA to skin snips, suggesting that the Ov16 RDT may be a useful tool for ivermectin STOP MDA and post transmission surveys, assuming that the prevalence of infection is low or close to zero, and the Ov16 RDT detected also pre patent infections.
  • ||||||||||  ivermectin oral / Generic mfg.
    Journal:  Dynamics of Plasmodium species and genotype diversity in adults with asymptomatic infection in Gabon. (Pubmed Central) -  May 5, 2024   
    Our results reveal complex intra-host dynamics of P. falciparum genotypes and Plasmodium species and underscore the importance of serial sampling in clinical trials for antimalarial drugs with asymptomatically P. falciparum-infected individuals. This might allow a more accurate identification of genotypes in multiple infections, impacting the assessment of drug efficacy.
  • ||||||||||  ivermectin oral / Generic mfg.
    Journal:  High Efficacy of Ivermectin for Strongyloidiasis Treatment. (Pubmed Central) -  May 1, 2024   
    Fecal samples were collected before and 2 weeks after treatment and were analyzed for the presence of Strongyloides using a modified agar plate culture and the formalin-ethyl acetate concentration technique. Our results showed that single-dose IVM treatment successfully eliminated S. stercoralis infection in asymptomatic individuals in the endemic area with a 100% cure rate, indicating the high efficacy of IVM treatment in strongyloidiasis in northeast Thailand.
  • ||||||||||  ivermectin oral / Generic mfg.
    Observational data, Journal:  Pulmonary and Gastrointestinal Parasitic Infections in Small Ruminant Autochthonous Breeds from Centre Region of Portugal-A Cross Sectional Study. (Pubmed Central) -  Apr 27, 2024   
    According to the binary logistic regression model, sheep dewormed with albendazole, mebendazole plus closantel, or ivermectin plus clorsulon presented a risk of Protostrongylidae infection 29.702, 7.426, or 8.720 times higher, respectively, than those dewormed with eprinomectin...Strongyle-type eggs were the most frequently identified, both in sheep (69.8%) and goats (87.8%), followed by Eimeria oocysts (40.3% in sheep and 68.9% in goats). Considering the high prevalence and the burden of lungworm parasitic infection, it is urgent to determine its economic impact and the repercussions in animal health in the Centre region of Portugal to establish appropriate therapeutic guidelines.
  • ||||||||||  ivermectin oral / Generic mfg.
    Journal:  Scabies in Infants: Series of 51 Cases. (Pubmed Central) -  Apr 27, 2024   
    Regarding treatment, 98% of the infants received topical permethrin and 35% received oral ivermectin...Living in large family units was associated with a higher risk of contagion and therapeutic failure. Diagnostic delay was associated with previous misdiagnosis.
  • ||||||||||  metformin / Generic mfg., ivermectin oral / Generic mfg., fluvoxamine / Generic mfg.
    Trial completion:  COVID-OUT: Early Outpatient Treatment for SARS-CoV-2 Infection (COVID-19) (clinicaltrials.gov) -  Apr 25, 2024   
    P3,  N=1323, Completed, 
    Diagnostic delay was associated with previous misdiagnosis. Active, not recruiting --> Completed
  • ||||||||||  ivermectin oral / Generic mfg.
    Trial completion date, Trial primary completion date:  Ivermectin Therapy for Scabies Infection in Children Younger Than 5 Years of Age (ITCHY Study) (clinicaltrials.gov) -  Apr 23, 2024   
    P2,  N=120, Not yet recruiting, 
    This study provides a starting point for further development of criteria for the evaluation of NT. Trial completion date: Jun 2024 --> Jun 2026 | Trial primary completion date: Jun 2024 --> Jun 2026